Approval from the German “Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)” to initiate a Compassionate Use Program (Härtefallprogramm) for pritelivir.
„Wir können lebenswichtige Medikamente zur Behandlung von COVID-19-Patienten zur Verfügung stellen, aber wir benötigen signifikante Unterstützung bei der Finanzierung der Entwicklungs- und Produktionskosten – jetzt!“
AiCuris has launched a four-pillar program, “PREP – Pandemic and Resistance Emergency Preparedness”
Royalty Pharma and AiCuris have entered into an agreement whereby Royalty Pharma has acquired a partial royalty interest on Prevymis™ (letermovir) from AiCuris for a one-time-payment of $220 million.
AiCuris has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for oral pritelivir, AiCuris’ lead candidate for the treatment of acyclovir-resistant mucocutaneous herpes simplex virus (HSV)
“In times like these, biotech and pharmaceutical companies have a great societal responsibility”
AiCuris and myTomorrows today announced a collaboration to develop an Early Access Program (EAP) for pritelivir, currently undergoing Phase II testing for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.
